The company is revising guidance for fiscal 2025 as follows: Organic net sales growth is expected to be down 2 to 4%.
The scheme aims to deliver affordable generic drugs, which can be 50-80% cheaper than branded varieties, but has been hobbled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback